Barrett’s esophagus is a complication of gastroesophageal reflux disease and is a manifestation of chronic tissue injury. It is characterized by the presence of intestinal metaplasia in an esophagus lined with cardiac-type mucosa; alternatively described as a columnar-lined esophagus with intestinal metaplasia or Barrett’s mucosal. When present, the abnormal mucosa confers a more than 30 to125-...

Background: Gastric cancer is an important health problem across the world. Chemotherapy in combination with local treatment is standard treatment for locally advanced gastroesophageal cancers. The purpose of this investigation was evaluation of response and tolerability to neoadjuvant EOX regimen in locoregionally advanced gastric cancer. Materials and Methods: patients with locoregionally adv...

BACKGROUND Gastrointestinal cancers are among the leading causes of cancer-related deaths worldwide. In different tumor types, personalized systemic treatment strategies based upon biomarker-selection were established over the last years. Although there is a flood of targeted agents in clinical development, only a few targeted agents with a predictive biomarker could be established for the trea...

Barrett's esophagus is an epithelial metaplasia associated with an increased risk for cancer, but its underlying mechanisms have been debated. Now Wang et al. (2011) suggest an intriguing explanation for this puzzle: a population of residual embryonic cells, lacking the transcription factor p63, migrates and repopulates a normal tissue damaged by inflammation or gastroesophageal reflux.

abstract background: esophageal cancer is one of the major malignancies, with various epidemiological aspects in recent years in developing countries, including increased prevalence and variations of pathologic patterns. this may be due to increasing rates of barrett’s esophagus, gastroesophageal reflux, smoking and obesity. this study was performed from 1991 to 2005 in order to evaluate variou...

background: recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. however, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. the present study evaluated the outcome and mid-term survival of patients with gastric ...

Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced...

Esophageal cancer often is asymptomatic until it has advanced or metastasized to distant organs, limiting treatment options. The 2 most common forms are squamous cell carcinomas that appear in the upper or midesophagus and esophageal adenocarcinomas that tend to occur lower in the esophagus or at the gastroesophageal junction. Since the 1980s higher rates of esophageal adenocarcinomas have been...

Carcinoma of unknown primary (CUP) is a rare metastatic disease in which tumor site cannot be identified. CUP diagnosis exclusion requiring prior workup to identify site. We present case 64-year-old male with vague abdominal pain, history gastroesophageal reflux (GERD), gastritis, esophagitis, hepatitis C, alcoholic pancreatitis, liver hemangioma, and Warthin tumor, family cancer that was found...

BACKGROUND Esophageal adenocarcinoma results from gastroesophageal reflux and develops along a sequence involving non-dysplastic Barrett's esophagus (NDBE), low- (LGD) and high-grade dysplasia (HGD). We aimed to examine the reported annual cancer risk for NDBE in persons with symptoms of gastroesophageal reflux disease, i.e. symptomatic NDBE. MATERIALS AND METHODS Our study reviewed seven pop...